Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Cleveland State University currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio exhibits a high degree of fragmentation, as these actions are spread across 3 distinct examiners and 3 distinct art units. This arrangement suggests that each pending matter is being evaluated independently within the USPTO's life sciences divisions. Such a spread indicates that the university's patenting efforts are not concentrated under a single technical or administrative path.
DICKINSON, PAUL W is identified as the busiest examiner for the university, though they are responsible for 1 pending office action. Because the 3 pending actions are divided among 3 distinct examiners, no single examiner holds a majority of the active workload. This distribution across 3 distinct art units may reflect a broad research and development focus within the university's biotechnology patenting efforts. For the university, this means that prosecution strategies must be tailored to 3 different sets of examiner expectations and art unit guidelines. The presence of 3 distinct examiners ensures that the portfolio's outcomes are not dependent on any single individual's review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 1 | 63.2% | +9.6% |
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
| THROWER, LARRY W | 1 | 65.9% | +12.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18235920 | TUMOR RESECTION PROCESS AND COMPOSITION CONTAINING IRIDIUM-CONTAINING NUCLEOSIDE | DICKINSON, PAUL W | — |
| 17706997 | INFECTION-RESISTANT AND BIOACTIVE INTERBODY DEVICE, AND ASSOCIATED COMPOSTION AND METHOD | THROWER, LARRY W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17987058 | COMPOSITIONS AND METHODS OF TREATMENT OF SICKLE CELL ANEMIA AND BETA-THALASSEMIA | HALVORSON, MARK | — |
| 17706997 | INFECTION-RESISTANT AND BIOACTIVE INTERBODY DEVICE, AND ASSOCIATED COMPOSTION AND METHOD | THROWER, LARRY W | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1646 | 1 |
| 1754 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18235920 | TUMOR RESECTION PROCESS AND COMPOSITION CONTAINING IRIDIUM-CONTAINING NUCLEOSIDE | DICKINSON, PAUL W | 1618 | §103§112 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 17987058 | COMPOSITIONS AND METHODS OF TREATMENT OF SICKLE CELL ANEMIA AND BETA-THALASSEMIA | HALVORSON, MARK | 1646 | §112 | Non-Final OA | — | Pending | Nov 15, 2022 |
| 17706997 | INFECTION-RESISTANT AND BIOACTIVE INTERBODY DEVICE, AND ASSOCIATED COMPOSTION AND METHOD | THROWER, LARRY W | 1754 | §102§103 | Final Rejection | — | Pending | Mar 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCleveland State University has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Paul W Dickinson has the most, with 1 of Cleveland State University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
